A101

The Antera Brand Back at the Summit of Light Alloy-wheel Producers

Retrieved on: 
水曜日, 4月 24, 2024
Sports, Automotive, General Automotive, Vehicle Technology, Automotive Manufacturing, Manufacturing, Soccer, Tires & Rubber, Recreational Vehicles, Diamond, Personality, A105, System, Soka Gakkai, AIDS, Research, Number 10, Life, Culture, Tree, Instinct, A101, Art, Football, LAB, Philosophy, PV, Panther, Perseverance, Hand, Communication, HPE, Dalla, Aggression, Pinguini Tattici Nucleari, A107, Netflix, Eye, Broadway Cares/Equity Fights AIDS, ALS, Aluminium, Child, HIV, Milan Furniture Fair, Brazilian, Compromise, Nature, Hospital, Dream, Heart, Collection, Diodato, FEM, Engineering, Coppa Italia, Multimedia, Beauty, Autobiography, Made in Italy, Courage, Casting, Serie A, History, A103, Banca Ifis, ESG, Creativity, CO2, Ikeda, Growth, Corporate governance, Fashion design

The Antera brand makes its comeback on the world stage during the 2024 Milan Design Week with a new collection of light alloy wheels.

Key Points: 
  • The Antera brand makes its comeback on the world stage during the 2024 Milan Design Week with a new collection of light alloy wheels.
  • A premium made-in-Italy brand, Antera combines timeless design, cutting-edge technology, and the determination to overcome any obstacle.
  • The new Antera collection features five different models of various dimensions, from 19 inches to 24 inches, and seven finishes.
  • Today, on the occasion of the 2024 Milan Design Week, the prestigious Antera brand makes its comeback on the global scene with a new collection of light alloy wheels for the automotive industry.

4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases

Retrieved on: 
水曜日, 1月 3, 2024
Biology, Entrepreneurship, Partnership, ALS, Gene editing, Cardiology, A101, Drug development, R100, Protein engineering, FDA, CRISPR, Cystic fibrosis, Disease, Tissue, Brain, PAMS, Vivisection, AAV, Artificial intelligence, DSM-IV codes, Ophthalmology, CNS, Engineering, Machine learning, Genome, Central nervous system, Patient, Therapy, Vaccine

Arbor also has expertise in CNS biology, CNS drug development and CNS therapeutic development.

Key Points: 
  • Arbor also has expertise in CNS biology, CNS drug development and CNS therapeutic development.
  • 4DMT has utilized its platform to invent customized AAV vectors for CNS tissues, and these vectors will be deployed in the partnership.
  • “CNS disorders include some of the most devastating diseases, many of which have a genetic origin.
  • We look forward to combining our complementary technologies and capabilities to power a new generation of potential genetic medicines.

4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases

Retrieved on: 
水曜日, 1月 3, 2024
Biology, Entrepreneurship, Partnership, ALS, Gene editing, Cardiology, A101, Drug development, R100, Protein engineering, FDA, CRISPR, Cystic fibrosis, Disease, Tissue, Brain, PAMS, Vivisection, AAV, Artificial intelligence, DSM-IV codes, Ophthalmology, CNS, Engineering, Machine learning, Genome, Central nervous system, Patient, Therapy, Vaccine

Arbor also has expertise in CNS biology, CNS drug development and CNS therapeutic development.

Key Points: 
  • Arbor also has expertise in CNS biology, CNS drug development and CNS therapeutic development.
  • 4DMT has utilized its platform to invent customized AAV vectors for CNS tissues, and these vectors will be deployed in the partnership.
  • “CNS disorders include some of the most devastating diseases, many of which have a genetic origin.
  • We look forward to combining our complementary technologies and capabilities to power a new generation of potential genetic medicines.

4D Molecular Therapeutics Announces Updates on Clinical Pipeline and Additional Preclinical Programs

Retrieved on: 
月曜日, 1月 9, 2023
IND, Disease, Partner (business rank), Echocardiography, PRISM, Clinical trial, Heart, Dialysis, A101, MD, GA, M.A, Degenerative disease, CF, Initiation, University of Nevada, Reno, Biopsy, Interim, NIH, QOL, University, IHC, Cystic fibrosis, Kidney, AMD, Toxic leukoencephalopathy, Intravitreal administration, RNA, Drug discovery, MRI, Choroideremia, Real-time, GMP, Stanford University School of Medicine, Development, Ahus, Fabry disease, Geographic atrophy, FDA, Retinitis pigmentosa, KCCQ, Addition, Atypical hemolytic uremic syndrome, Fabry, Principal, Ophthalmology, VG, Pulmonology, Enzyme replacement therapy, CFTR, DME, Clinical research, Safety, Diabetic retinopathy, ISH, Modulation, Pharmaceutical industry, Vaccine, 3D printing, Medical imaging, Patient

The doses to be evaluated in DME are expected to be similar to those used in the 4D-150 wet AMD clinical trial.

Key Points: 
  • The doses to be evaluated in DME are expected to be similar to those used in the 4D-150 wet AMD clinical trial.
  • It is estimated that there are over one million individuals with GA in the United States according to published data.
  • In addition, I’m excited by the potential of 4D-175, the new preclinical product candidate utilizing the same R100 vector.
  • Cardiac clinical endpoint data (MRI, echocardiography, cardiopulmonary exercise testing [CPET] and QOL assessment) from evaluations at baseline and 12 months after treatment were assessed.